Healthy Older AdultsIRENCT04353947
Induction and Recognition of Emotions
An observational study of Healthy Older Adults and Alzheimer's Disease, run by University of Valencia at 1 site in Spain.
Trial summary
This study evaluates the differences in cognitive function between healthy older adults, older adults with mild Alzheimer's type dementia and older adults with Parkinson's disease and if there are differences in valence assessment and activation that produce them a mood induction task. Read more about this study
- Who is it for?
- Ages 65 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Older Adults, Alzheimer's Disease, Parkinson's Disease
- What is being tested?
- Mini Cognitive Examination (MCE), Beck Depression Inventory-II (BDI-II) and Global Deterioration Scale (GDS)
- How many people
- 0 participants
- Where
- 1 siteSpain
- Study dates
- 2 Mar 2020to 30 Nov 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 99 years
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: * Healthy older adults will be recruited from the Third Age Classrooms of the municipality of Quart de Poblet. * The older adults with mild Alzheimer's disease will be recruited through the Neurology Department of the General Hospital of Valencia. * The older adults with Parkinson's disease will be recruited through the Valencia Parkinson Association.
Who may be able to join
- For the group of healthy older adults:
- MEC score greater than 26 points.
- GDS between 1 and 3.
- For the mild EA group:
- MEC score between 18 and 23 points.
- GDS between 3 and 4.
Show all 17Show fewer
- For the EP group:
- MEC score greater than 23 points.
- GDS between 1 and 3.
- FAB score equal to or less than 11 points.
- General Exclusion Criteria:
- Participants cannot have:
- Significant asymptomatic neurovascular disease
- History of previous symptomatic stroke
- Alcohol or drug abuse/dependence
- Severe psychiatric symptoms
- Depressive symptoms higher than mild
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Induction and Recognition of Emotions in Healthy Older Adults, Alzheimer's Disease and Parkinson's Disease
This study evaluates the differences in cognitive function between healthy older adults, older adults with mild Alzheimer's type dementia and older adults with Parkinson's disease and if there are differences in valence assessment and activation that produce them a mood induction task. Subjects are assessed using neuropsychological tests and then a mood induction task based on movie clips is applied.
Read the detailed description
Different neuropsychological tests will be used to assess the differences in cognitive function in the different groups, whose scores are expected to be lower in the group of older adults with Alzheimer's disease (AD) and older adults with Parkinson's disease (PD).
After studying the cognitive function in the different groups, we proceed to check through a task based on movie clips if there are also differences in the valence assessment (liking/disliking depending on the emotion induced by scenes from different films) and activation (excitement caused by each one of the movie scenes), hoping to find differences for the negative emotions taking into account the cognitive difficulties that both (the EA group and the EP group) may have for processing this type of cognitively more demanding information; instead, it is possible that the positivity effect continues to affect these patients so that for positive emotions there are no differences between the different groups.
- Being tested
- Mini Cognitive Examination (MCE), Beck Depression Inventory-II (BDI-II), Global Deterioration Scale (GDS), Memory alteration test (M@T), Spanish-Complutense Verbal Learning Test (TAVEC)
- Keywords
- Healthy older adults, Alzheimer's disease, Parkinson's disease, Mood induction, Positive emotions, Negative emotions
- Medical subject headings
- Alzheimer Disease, Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mini Cognitive Examination (MCE)Diagnostic test
This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
Beck Depression Inventory-II (BDI-II)Diagnostic test
This test evaluates the absence or presence of depressive symptoms.
Global Deterioration Scale (GDS)Diagnostic test
This scale measures the level of deterioration of the subject.
Memory alteration test (M@T)Diagnostic test
In this test different memory subtypes are evaluated.
Spanish-Complutense Verbal Learning Test (TAVEC)Diagnostic test
This test is used to assess immediate memory, deferred memory and learning ability.
Barcelona test (BT)Diagnostic test
This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category "animals" in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter "p" in 3 minutes.
Rey-Osterrieth Complex Figure Test (ROCFT)Diagnostic test
In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
Frontal assessment battery (FAB)Diagnostic test
This test is a composite tool for assessing executive functions related to the frontal lobe.
Positive and Negative Affect Scale (PANAS)Diagnostic test
It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
Auto-Assessment Manikins (SAM)Diagnostic test
It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
| Study group | Role | What they receive |
|---|---|---|
| Healthy older adults | Healthy older adults with 65 years or older Receives: Diagnostic Test: Mini Cognitive Examination (MCE); Diagnostic Test: Beck Depression Inventory-II (BDI-II); Diagnostic Test: Global Deterioration Scale (GDS); Diagnostic Test: Memory alteration test (M@T); Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC); Diagnostic Test: Barcelona test (BT); Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT); Diagnostic Test: Positive and Negative Affect Scale (PANAS); Diagnostic Test: Auto-Assessment Manikins (SAM) | |
| Older adults with Alzheimer's disease | Older adults with Alzheimer's disease with 65 years or older Receives: Diagnostic Test: Mini Cognitive Examination (MCE); Diagnostic Test: Beck Depression Inventory-II (BDI-II); Diagnostic Test: Global Deterioration Scale (GDS); Diagnostic Test: Memory alteration test (M@T); Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC); Diagnostic Test: Barcelona test (BT); Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT); Diagnostic Test: Positive and Negative Affect Scale (PANAS); Diagnostic Test: Auto-Assessment Manikins (SAM) | |
| Older adults with Parkinson's disease | Older adults with Alzheimer's disease with 65 years or older Receives: Diagnostic Test: Mini Cognitive Examination (MCE); Diagnostic Test: Beck Depression Inventory-II (BDI-II); Diagnostic Test: Global Deterioration Scale (GDS); Diagnostic Test: Memory alteration test (M@T); Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC); Diagnostic Test: Barcelona test (BT); Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT); Diagnostic Test: Frontal assessment battery (FAB); Diagnostic Test: Positive and Negative Affect Scale (PANAS); Diagnostic Test: Auto-Assessment Manikins (SAM) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mini-Mental State Examination (MMSE)
This test is evaluated on a maximum of 30 points. Participants with scores equal to or below 23 would be considered cognitively deficient.
Measured: 5-10 minutes
Beck Depression Inventory-II (BDI-II)
In this test, a score of 0-13 indicates absence of depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression.
Measured: 5-10 minutes
Global Deterioration Scale (GDS)
This scale indicates seven possible stages: 1. Absence of Cognitive Deficit; 2. Very slight cognitive deficit; 3. Mild Cognitive Deficit; 4. Moderate cognitive deficit; 5. Moderately severe cognitive deficit; 6. Severe cognitive deficit; 7. Very severe cognitive deficit.
Measured: 30 minutes
Memory alteration test (M@T)
This cognitive test is evaluated on a maximum of 50 points. The optimal cut-off point for distinguishing mild cognitive impairment of the amnesiac type from subjective memory complaints is 37 points. The optimal cut-off point for Alzheimer's disease is 31 points.
Measured: 5-10 minutes
Spanish-Complutense Verbal Learning Test (TAVEC)
The evaluator reads a 16-word shopping list in five different essays and in each of them the evaluated person must mention those words that he or she remembers. After 20 minutes, the subject is asked to remember them again.
Measured: 30 minutes
Barcelona test (BT)
In this test, the subject is considered to have a good categorical evocation when he is able to evoke more than 16 animals in 1 minute and a good verbal fluency when he is able to evoke more than 19 words beginning with "p" in 3 minutes.
Measured: 5 minutes
Rey-Osterrieth Complex Figure Test (ROCFT)
The direct score (PD) in the copy of the Rey figure that would leave 50% of the population below is 30 points, while in the reproduction of the Rey figure from memory the PD that would leave 50% below of the population is 21 points.
Measured: 10 minutes
Frontal assessment battery (FAB)
The maximum score to be obtained in this test is 18 points. To consider that the subject presents alterations in the frontal lobe and, therefore, altered executive functions, his score must be equal to or less than 11 points.
Measured: 10 minutes
Positive and Negative Affect Scale (PANAS)
The final score of this scale is the sum of the 10 terms on the positive scale and the sum of the 10 terms on the negative scale, with the value assigned for the responses on the positive scale being positive and negative for the responses on the negative scale.
Measured: 10 minutes
Auto-Assessment Manikins (SAM)
This questionnaire measures the valence (liking/disliking depending on the emotion induced by scenes from different movies), the arousal (excitement caused by each of the movie scenes) and mastery or emotional control (self-perception of the control exerted on the environment and the emotion itself).
Measured: 5-10 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2020
- Study start2 Mar 2020
- Primary completion30 Oct 2020 (estimated)
- Study completion30 Nov 2020 (estimated)
Why it stopped: COVID 19
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Healthy Older AdultsStudies of the same condition, open and under way.
- More trials run by University of ValenciaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Valencia
- Sponsor type
- University, hospital or other
- Collaborators
- Asociación Parkinson Valencia
- Responsible party
- Sponsor
- Investigators
- Juan C Melendez, Psychology, Principal investigator, University of Valencia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04353947
- Sponsor's protocol ID
- UV-INV_ETICA-1217558
- Acronym
- IRE
- Status last verified
- May 2021
- First submitted
- 16 Apr 2020
- Last updated
- 6 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: All the information of the study, as well as its results, will be shared in scientific publications and conferences related to the research area. The information that is intended to be published in scientific journals includes: 1) Study Protocol, 2) Statistical Analysis, 3) Informed Consent Form, 4) Clinical Study Results.
Publications
Fernandez-Aguilar L, Ricarte J, Ros L, Latorre JM. Emotional Differences in Young and Older Adults: Films as Mood Induction Procedure. Front Psychol. 2018 Jul 3;9:1110. doi: 10.3389/fpsyg.2018.01110. eCollection 2018.
PubMed 30018584Carvalho S, Leite J, Galdo-Alvarez S, Goncalves OF. The Emotional Movie Database (EMDB): a self-report and psychophysiological study. Appl Psychophysiol Biofeedback. 2012 Dec;37(4):279-94. doi: 10.1007/s10484-012-9201-6.
PubMed 22767079Alves H, Koch A, Unkelbach C. Why Good Is More Alike Than Bad: Processing Implications. Trends Cogn Sci. 2017 Feb;21(2):69-79. doi: 10.1016/j.tics.2016.12.006. Epub 2017 Jan 4.
PubMed 28063663Alves H, Koch A, Unkelbach C. The differential similarity of positive and negative information - an affect-induced processing outcome? Cogn Emot. 2019 Sep;33(6):1224-1238. doi: 10.1080/02699931.2018.1549022. Epub 2018 Nov 26.
PubMed 30475089Reed AE, Carstensen LL. The theory behind the age-related positivity effect. Front Psychol. 2012 Sep 27;3:339. doi: 10.3389/fpsyg.2012.00339. eCollection 2012.
PubMed 23060825Nashiro K, Mather M. Effects of emotional arousal on memory binding in normal aging and Alzheimer's disease. Am J Psychol. 2011 Fall;124(3):301-12. doi: 10.5406/amerjpsyc.124.3.0301.
PubMed 21977692
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Induction and Recognition of Emotions in Healthy Older Adults, Alzheimer's Disease and Parkinson's Disease
- ClinicalTrials.gov ID
- NCT04353947
- Acronym / sponsor ID
- IRE / UV-INV_ETICA-1217558
- Keywords
- Healthy older adults, Alzheimer's disease, Parkinson's disease, Mood induction, Positive emotions, Negative emotions
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: COVID 19
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of ValenciaUniversity, hospital or other
- Collaborators
- Asociación Parkinson Valencia
- Study start
- 2 Mar 2020 (actual)
- Primary completion
- 30 Oct 2020 (estimated)
- Study completion
- 30 Nov 2020 (estimated)
- First posted
- 21 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the differences in cognitive function between healthy older adults, older adults with mild Alzheimer's type dementia and older adults with Parkinson's disease and if there are differences in valence assessment and activation that produce them a mood induction task. Subjects are assessed using neuropsychological tests and then a mood induction task based on movie clips is applied.
Detailed description
Different neuropsychological tests will be used to assess the differences in cognitive function in the different groups, whose scores are expected to be lower in the group of older adults with Alzheimer's disease (AD) and older adults with Parkinson's disease (PD).
After studying the cognitive function in the different groups, we proceed to check through a task based on movie clips if there are also differences in the valence assessment (liking/disliking depending on the emotion induced by scenes from different films) and activation (excitement caused by each one of the movie scenes), hoping to find differences for the negative emotions taking into account the cognitive difficulties that both (the EA group and the EP group) may have for processing this type of cognitively more demanding information; instead, it is possible that the positivity effect continues to affect these patients so that for positive emotions there are no differences between the different groups.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Healthy older adults | – | Diagnostic Test: Mini Cognitive Examination (MCE), Diagnostic Test: Beck Depression Inventory-II (BDI-II), Diagnostic Test: Global Deterioration Scale (GDS), Diagnostic Test: Memory alteration test (M@T), Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC), Diagnostic Test: Barcelona test (BT), Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT), Diagnostic Test: Positive and Negative Affect Scale (PANAS), Diagnostic Test: Auto-Assessment Manikins (SAM)Healthy older adults with 65 years or older |
| Older adults with Alzheimer's disease | – | Diagnostic Test: Mini Cognitive Examination (MCE), Diagnostic Test: Beck Depression Inventory-II (BDI-II), Diagnostic Test: Global Deterioration Scale (GDS), Diagnostic Test: Memory alteration test (M@T), Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC), Diagnostic Test: Barcelona test (BT), Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT), Diagnostic Test: Positive and Negative Affect Scale (PANAS), Diagnostic Test: Auto-Assessment Manikins (SAM)Older adults with Alzheimer's disease with 65 years or older |
| Older adults with Parkinson's disease | – | Diagnostic Test: Mini Cognitive Examination (MCE), Diagnostic Test: Beck Depression Inventory-II (BDI-II), Diagnostic Test: Global Deterioration Scale (GDS), Diagnostic Test: Memory alteration test (M@T), Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC), Diagnostic Test: Barcelona test (BT), Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT), Diagnostic Test: Frontal assessment battery (FAB), Diagnostic Test: Positive and Negative Affect Scale (PANAS), Diagnostic Test: Auto-Assessment Manikins (SAM)Older adults with Alzheimer's disease with 65 years or older |
Who may qualify
- Ages
- 65 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- * Healthy older adults will be recruited from the Third Age Classrooms of the municipality of Quart de Poblet. * The older adults with mild Alzheimer's disease will be recruited through the Neurology Department of the General Hospital of Valencia. * The older adults with Parkinson's disease will be recruited through the Valencia Parkinson Association.
Key inclusion criteria (17 listed)
- MEC score greater than 26 points.
- GDS between 1 and 3.
- MEC score between 18 and 23 points.
- GDS between 3 and 4.
- MEC score greater than 23 points.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mini Cognitive Examination (MCE)This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Beck Depression Inventory-II (BDI-II)This test evaluates the absence or presence of depressive symptoms. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Global Deterioration Scale (GDS)This scale measures the level of deterioration of the subject. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Memory alteration test (M@T)In this test different memory subtypes are evaluated. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Spanish-Complutense Verbal Learning Test (TAVEC)This test is used to assess immediate memory, deferred memory and learning ability. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Barcelona test (BT)This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category "animals" in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter "p" in 3 minutes. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Rey-Osterrieth Complex Figure Test (ROCFT)In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Frontal assessment battery (FAB)This test is a composite tool for assessing executive functions related to the frontal lobe. | Diagnostic test | Older adults with Parkinson's disease |
| Positive and Negative Affect Scale (PANAS)It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale). | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
| Auto-Assessment Manikins (SAM)It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes. | Diagnostic test | Healthy older adults, Older adults with Alzheimer's disease, Older adults with Parkinson's disease |
Primary outcome
Mini-Mental State Examination (MMSE)
Time frame: 5-10 minutes
This test is evaluated on a maximum of 30 points. Participants with scores equal to or below 23 would be considered cognitively deficient.
Beck Depression Inventory-II (BDI-II)
Time frame: 5-10 minutes
In this test, a score of 0-13 indicates absence of depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression.
Global Deterioration Scale (GDS)
Time frame: 30 minutes
This scale indicates seven possible stages: 1. Absence of Cognitive Deficit; 2. Very slight cognitive deficit; 3. Mild Cognitive Deficit; 4. Moderate cognitive deficit; 5. Moderately severe cognitive deficit; 6. Severe cognitive deficit; 7. Very severe cognitive deficit.
Memory alteration test (M@T)
Time frame: 5-10 minutes
This cognitive test is evaluated on a maximum of 50 points. The optimal cut-off point for distinguishing mild cognitive impairment of the amnesiac type from subjective memory complaints is 37 points. The optimal cut-off point for Alzheimer's disease is 31 points.
Spanish-Complutense Verbal Learning Test (TAVEC)
Time frame: 30 minutes
The evaluator reads a 16-word shopping list in five different essays and in each of them the evaluated person must mention those words that he or she remembers. After 20 minutes, the subject is asked to remember them again.
Barcelona test (BT)
Time frame: 5 minutes
In this test, the subject is considered to have a good categorical evocation when he is able to evoke more than 16 animals in 1 minute and a good verbal fluency when he is able to evoke more than 19 words beginning with "p" in 3 minutes.
Rey-Osterrieth Complex Figure Test (ROCFT)
Time frame: 10 minutes
The direct score (PD) in the copy of the Rey figure that would leave 50% of the population below is 30 points, while in the reproduction of the Rey figure from memory the PD that would leave 50% below of the population is 21 points.
Frontal assessment battery (FAB)
Time frame: 10 minutes
The maximum score to be obtained in this test is 18 points. To consider that the subject presents alterations in the frontal lobe and, therefore, altered executive functions, his score must be equal to or less than 11 points.
Positive and Negative Affect Scale (PANAS)
Time frame: 10 minutes
The final score of this scale is the sum of the 10 terms on the positive scale and the sum of the 10 terms on the negative scale, with the value assigned for the responses on the positive scale being positive and negative for the responses on the negative scale.
Auto-Assessment Manikins (SAM)
Time frame: 5-10 minutes
This questionnaire measures the valence (liking/disliking depending on the emotion induced by scenes from different movies), the arousal (excitement caused by each of the movie scenes) and mastery or emotional control (self-perception of the control exerted on the environment and the emotion itself).
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2021.
- Results publication: PubMed 30018584Fernandez-Aguilar L, Ricarte J, Ros L, Latorre JM. Emotional Differences in Young and Older Adults: Films as Mood Induction Procedure. Front Psychol. 2018 Jul 3;9:1110. doi: 10.3389/fpsyg.2018.01110. eCollection 2018.
- Results publication: PubMed 22767079Carvalho S, Leite J, Galdo-Alvarez S, Goncalves OF. The Emotional Movie Database (EMDB): a self-report and psychophysiological study. Appl Psychophysiol Biofeedback. 2012 Dec;37(4):279-94. doi: 10.1007/s10484-012-9201-6.
- Results publication: PubMed 28063663Alves H, Koch A, Unkelbach C. Why Good Is More Alike Than Bad: Processing Implications. Trends Cogn Sci. 2017 Feb;21(2):69-79. doi: 10.1016/j.tics.2016.12.006. Epub 2017 Jan 4.
- Results publication: PubMed 30475089Alves H, Koch A, Unkelbach C. The differential similarity of positive and negative information - an affect-induced processing outcome? Cogn Emot. 2019 Sep;33(6):1224-1238. doi: 10.1080/02699931.2018.1549022. Epub 2018 Nov 26.
- Results publication: PubMed 23060825Reed AE, Carstensen LL. The theory behind the age-related positivity effect. Front Psychol. 2012 Sep 27;3:339. doi: 10.3389/fpsyg.2012.00339. eCollection 2012.
- Results publication: PubMed 21977692Nashiro K, Mather M. Effects of emotional arousal on memory binding in normal aging and Alzheimer's disease. Am J Psychol. 2011 Fall;124(3):301-12. doi: 10.5406/amerjpsyc.124.3.0301.
- Individual participant dataSharing planned: No. All the information of the study, as well as its results, will be shared in scientific publications and conferences related to the research area. The information that is intended to be published in scientific journals includes: 1) Study Protocol, 2) Statistical Analysis, 3) Informed Consent Form, 4) Clinical Study Results.
Related trials for Healthy Older Adults
Active, not recruitingPhase 3
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
Pneumococcal Disease
Not yet recruiting
Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot Study
Healthy Aging, Cognition
Recruiting
Intervention Program for Psychological Well-Being in Institutionalized Older Adults Through Virtual Reality
Healthy Volunteers, Aging, Healthy
Active, not recruiting
An Effectiveness Evaluation for Pathway to Healthy Aging (Path-HA) Care on Health Status of Older Adults
Ageing Well
Not yet recruiting
Effectiveness of a Smartphone Chatbot to Improve Exercise Adherence in Older Adults
Exercise Adherence, Healthy Aging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Juan C Melendez, Psychology principal investigator
University of Valencia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy Older Adults and Alzheimer's Disease, run by University of Valencia at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 6 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mini-Mental State Examination (MMSE) (time frame: 5-10 minutes). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04353947, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2021.